151 related articles for article (PubMed ID: 24753433)
1. Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.
Ferl GZ; O'Connor JP; Parker GJ; Carano RA; Acharya SJ; Jayson GC; Port RE
J Magn Reson Imaging; 2015 Jan; 41(1):132-41. PubMed ID: 24753433
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.
Craciunescu OI; Yoo DS; Cleland E; Muradyan N; Carroll MD; MacFall JR; Barboriak DP; Brizel DM
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e345-50. PubMed ID: 21985945
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
Kickingereder P; Wiestler B; Graf M; Heiland S; Schlemmer HP; Wick W; Wick A; Bendszus M; Radbruch A
J Neurooncol; 2015 Jan; 121(2):373-80. PubMed ID: 25359396
[TBL] [Abstract][Full Text] [Related]
5. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.
O'Connor JP; Rose CJ; Jackson A; Watson Y; Cheung S; Maders F; Whitcher BJ; Roberts C; Buonaccorsi GA; Thompson G; Clamp AR; Jayson GC; Parker GJ
Br J Cancer; 2011 Jun; 105(1):139-45. PubMed ID: 21673686
[TBL] [Abstract][Full Text] [Related]
6. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.
Kim YE; Joo B; Park MS; Shin SJ; Ahn JB; Kim MJ
Cancer Res Treat; 2016 Oct; 48(4):1210-1221. PubMed ID: 26987390
[TBL] [Abstract][Full Text] [Related]
7. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
[TBL] [Abstract][Full Text] [Related]
9. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
van Laarhoven HW; Klomp DW; Rijpkema M; Kamm YL; Wagener DJ; Barentsz JO; Punt CJ; Heerschap A
NMR Biomed; 2007 Apr; 20(2):128-40. PubMed ID: 17006886
[TBL] [Abstract][Full Text] [Related]
10. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer.
Gollub MJ; Gultekin DH; Akin O; Do RK; Fuqua JL; Gonen M; Kuk D; Weiser M; Saltz L; Schrag D; Goodman K; Paty P; Guillem J; Nash GM; Temple L; Shia J; Schwartz LH
Eur Radiol; 2012 Apr; 22(4):821-31. PubMed ID: 22101743
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
[TBL] [Abstract][Full Text] [Related]
14. [Dynamic Contrast-enhanced Magnetic Resonance Imaging Permeability Parameters Monitor the Early Response to Bevacizumab Plus Chemotherapy in Colorectal Cancer Patients with Liver Metastases].
Liu D; Qian HF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Apr; 40(2):256-263. PubMed ID: 29724317
[TBL] [Abstract][Full Text] [Related]
15. Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and dynamic 18F-FDG-PET.
Vriens D; de Geus-Oei LF; Heerschap A; van Laarhoven HW; Oyen WJ
Clin Colorectal Cancer; 2011 Mar; 10(1):E1-5. PubMed ID: 21609927
[TBL] [Abstract][Full Text] [Related]
16. Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab.
Port RE; Bernstein LJ; Barboriak DP; Xu L; Roberts TP; van Bruggen N
Magn Reson Med; 2010 Aug; 64(2):408-17. PubMed ID: 20665785
[TBL] [Abstract][Full Text] [Related]
17. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
[TBL] [Abstract][Full Text] [Related]
18. Tumour subregion analysis of colorectal liver metastases using semi-automated clustering based on DCE-MRI: Comparison with histological subregions and impact on pharmacokinetic parameter analysis.
Franklin JM; Irving B; Papiez BW; Kallehauge JF; Wang LM; Goldin RD; Harris AL; Anderson EM; Schnabel JA; Chappell MA; Brady M; Sharma RA; Gleeson FV
Eur J Radiol; 2020 May; 126():108934. PubMed ID: 32217426
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate.
Vriens D; van Laarhoven HW; van Asten JJ; Krabbe PF; Visser EP; Heerschap A; Punt CJ; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2009 Nov; 50(11):1777-84. PubMed ID: 19837750
[TBL] [Abstract][Full Text] [Related]
20. Reduced respiratory motion artifacts using structural similarity in fast 2D dynamic contrast enhanced MRI of liver lesions.
Ter Voert EE; Heijmen L; Punt CJ; de Wilt JH; van Laarhoven HW; Heerschap A
NMR Biomed; 2016 Nov; 29(11):1526-1535. PubMed ID: 27598946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
